{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:49:10Z","timestamp":1768038550111,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>This is the first consensus statement of the Joint Committee on Renal Denervation of the Japanese Society of Hypertension (JSH)\/Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT)\/Japanese Circulation Society (JCS). The consensus is that the indication for renal denervation (RDN) is resistant hypertension or \u201cconditioned\u201d uncontrolled hypertension, with high office and out-of-office blood pressure (BP) readings despite appropriate lifestyle modification and antihypertensive drug therapy. \u201cConditioned\u201d uncontrolled hypertension is defined as having one of the following: 1) inability to up-titrate antihypertensive medication due to side effects, the presence of complications, or reduced quality of life. This includes patients who are intolerant of antihypertensive drugs; or 2) comorbidity at high cardiovascular risk due to increased sympathetic nerve activity, such as orthostatic hypertension, morning hypertension, nocturnal hypertension, or sleep apnea (unable to use continuous positive airway pressure), atrial fibrillation, ventricular arrythmia, or heart failure. RDN should be performed by the multidisciplinary Hypertension Renal Denervation Treatment (HRT) team, led by specialists in hypertension, cardiovascular intervention and cardiology, in specialized centers validated by JSH, CVIT, and JCS. The HRT team reviews lifestyle modifications and medication, and the patient profile, then determines the presence of an indication of RDN based on shared decision making with each patient. Once approval for real-world clinical use in Japan, however, the joint RDN committee will update the indication and treatment implementation guidance as appropriate (annually if necessary) based on future real-world evidence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s12928-024-01017-1","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T17:02:49Z","timestamp":1722358969000},"page":"376-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS)"],"prefix":"10.1007","volume":"39","author":[{"given":"Kazuomi","family":"Kario","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hoshide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Nanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"12","key":"1017_CR1","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jcin.2019.02.050","volume":"12","author":"MA Weber","year":"2019","unstructured":"Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, et al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv. 2019;12(12):1095\u2013105.","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"1017_CR2","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","volume":"44","author":"L Lauder","year":"2023","unstructured":"Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 2023;44(23):2066\u201377.","journal-title":"Eur Heart J"},{"issue":"2","key":"1017_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41440-021-00827-7","volume":"45","author":"K Katsurada","year":"2022","unstructured":"Katsurada K, Shinohara K, Aoki J, Nanto S, Kario K. Renal denervation: basic and clinical evidence. Hypertens Res. 2022;45(2):198\u2013209.","journal-title":"Hypertens Res"},{"issue":"9671","key":"1017_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H Krum","year":"2009","unstructured":"Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275\u201381.","journal-title":"Lancet"},{"issue":"9756","key":"1017_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"MD Esler","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903\u20139.","journal-title":"Lancet"},{"issue":"15","key":"1017_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393\u2013401.","journal-title":"N Engl J Med"},{"issue":"10137","key":"1017_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"M Azizi","year":"2018","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335\u201345.","journal-title":"Lancet"},{"issue":"10234","key":"1017_CR8","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M Bohm","year":"2020","unstructured":"Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444\u201351.","journal-title":"Lancet"},{"issue":"10293","key":"1017_CR9","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476\u201386.","journal-title":"Lancet"},{"issue":"2","key":"1017_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41440-021-00754-7","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45(2):221\u201331.","journal-title":"Hypertens Res"},{"issue":"8","key":"1017_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jama.2023.0713","volume":"329","author":"M Azizi","year":"2023","unstructured":"Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023;329(8):651\u201361.","journal-title":"JAMA"},{"issue":"19","key":"1017_CR12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","volume":"82","author":"DE Kandzari","year":"2023","unstructured":"Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1017_CR13","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1253\/circj.CJ-15-0150","volume":"79","author":"K Kario","year":"2015","unstructured":"Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in asian patients. Circ J. 2015;79(6):1222\u20139.","journal-title":"Circ J"},{"issue":"3","key":"1017_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1253\/circj.CJ-18-1018","volume":"83","author":"K Kario","year":"2019","unstructured":"Kario K, Yamamoto E, Tomita H, Okura T, Saito S, Ueno T, et al. Sufficient and persistent blood pressure reduction in the final long-term results from SYMPLICITY HTN-Japan - safety and efficacy of renal denervation at 3 years. Circ J. 2019;83(3):622\u20139.","journal-title":"Circ J"},{"issue":"12","key":"1017_CR15","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH buidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"3","key":"1017_CR16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1161\/HYPERTENSIONAHA.119.13671","volume":"75","author":"K Kario","year":"2020","unstructured":"Kario K, Kim BK, Aoki J, Wong AY, Lee YH, Wongpraparut N, et al. Renal denervation in Asia: consensus statement of the Asia renal denervation consortium. Hypertension. 2020;75(3):590\u2013602.","journal-title":"Hypertension"},{"issue":"3","key":"1017_CR17","first-page":"199","volume":"35","author":"TD Wang","year":"2019","unstructured":"Wang TD, Lee YH, Chang SS, Tung YC, Yeh CF, Lin YH, et al. 2019 consensus statement of the Taiwan hypertension society and the Taiwan society of cardiology on renal denervation for the management of arterial hypertension. Acta Cardiol Sin. 2019;35(3):199\u2013230.","journal-title":"Acta Cardiol Sin"},{"issue":"9","key":"1017_CR18","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1097\/HJH.0000000000002933","volume":"39","author":"RE Schmieder","year":"2021","unstructured":"Schmieder RE, Mahfoud F, Mancia G, Azizi M, Bohm M, Dimitriadis K, et al. European Society of hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733\u201341.","journal-title":"J Hypertens"},{"issue":"7","key":"1017_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41440-022-00937-w","volume":"45","author":"YC Chia","year":"2022","unstructured":"Chia YC, Wan Ahmad WA, Fong AYY, Rosman A, Abdul Rahman AR, Choo GH, et al. 2022 Malaysian working group consensus statement on renal denervation for management of arterial hypertension. Hypertens Res. 2022;45(7):1111\u201322.","journal-title":"Hypertens Res"},{"issue":"15","key":"1017_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","volume":"44","author":"E Barbato","year":"2023","unstructured":"Barbato E, Azizi M, Schmieder RE, Lauder L, Bohm M, Brouwers S, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44(15):1313\u201330.","journal-title":"Eur Heart J"},{"issue":"12","key":"1017_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00392-019-01468-0","volume":"108","author":"RE Schmieder","year":"2019","unstructured":"Schmieder RE, Hogerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12):1331\u201342.","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"1017_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41440-021-00760-9","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45(2):232\u201340.","journal-title":"Hypertens Res"},{"issue":"9","key":"1017_CR23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235\u2013481.","journal-title":"Hypertens Res"},{"issue":"Pt B","key":"1017_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.phrs.2017.08.015","volume":"125","author":"M Burnier","year":"2017","unstructured":"Burnier M. Drug adherence in hypertension. Pharmacol Res. 2017;125(Pt B):142\u20139.","journal-title":"Pharmacol Res"},{"issue":"10199","key":"1017_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(19)31629-0","volume":"394","author":"IJ Benjamin","year":"2019","unstructured":"Benjamin IJ, Kreutz R, Olsen MH, Schutte AE, Lopez-Jaramillo P, Frieden TR, et al. Fixed-dose combination antihypertensive medications. Lancet. 2019;394(10199):637\u20138.","journal-title":"Lancet"},{"issue":"9","key":"1017_CR26","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1097\/HJH.0000000000002096","volume":"37","author":"A Salam","year":"2019","unstructured":"Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(9):1768\u201374.","journal-title":"J Hypertens"},{"issue":"2","key":"1017_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41440-022-01087-9","volume":"46","author":"K Kario","year":"2023","unstructured":"Kario K, Tomitani N, Nishizawa M, Harada N, Kanegae H, Hoshide S. Concept, study design, and baseline blood pressure control status of the nationwide prospective HI-JAMP study using multisensor ABPM. Hypertens Res. 2023;46(2):357\u201367.","journal-title":"Hypertens Res"},{"issue":"4","key":"1017_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41371-017-0025-y","volume":"32","author":"S Park","year":"2018","unstructured":"Park S, Buranakitjaroen P, Chen CH, Chia YC, Divinagracia R, Hoshide S, et al. Expert panel consensus recommendations for home blood pressure monitoring in Asia: the Hope Asia Network. J Hum Hypertens. 2018;32(4):249\u201358.","journal-title":"J Hum Hypertens"},{"issue":"3","key":"1017_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/jch.13216","volume":"20","author":"K Kario","year":"2018","unstructured":"Kario K, Park S, Buranakitjaroen P, Chia YC, Chen CH, Divinagracia R, et al. Guidance on home blood pressure monitoring: A statement of the HOPE Asia Network. J Clin Hypertens (Greenwich). 2018;20(3):456\u201361.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"1017_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/jch.13751","volume":"22","author":"K Kario","year":"2020","unstructured":"Kario K, Park S, Chia YC, Sukonthasarn A, Turana Y, Shin J, et al. 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia network. J Clin Hypertens (Greenwich). 2020;22(3):351\u201362.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"12","key":"1017_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/jhh.2010.54","volume":"24","author":"G Parati","year":"2010","unstructured":"Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European society of hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24(12):779\u201385.","journal-title":"J Hum Hypertens"},{"issue":"3","key":"1017_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jch.14128","volume":"23","author":"K Kario","year":"2021","unstructured":"Kario K, Hoshide S, Chia YC, Buranakitjaroen P, Siddique S, Shin J, et al. Guidance on ambulatory blood pressure monitoring: a statement from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2021;23(3):411\u201321.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"1017_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41440-022-01137-2","volume":"46","author":"M Cepeda","year":"2023","unstructured":"Cepeda M, Pham P, Shimbo D. Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of hypertension in the US: an up-to-date review. Hypertens Res. 2023;46(3):620\u20139.","journal-title":"Hypertens Res"},{"issue":"6","key":"1017_CR34","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269\u2013324.","journal-title":"Hypertension"},{"key":"1017_CR35","unstructured":"Kario K, SPYRAL HTN-OFF MED trial group. Orthostatic hypertension as potential identifier of responders to renal denervation: Post-hoc analysis from the SPYRAL HTN-OFF MED trial. Paper presented at: American Heart Association Scientific Meeting 2019; Nov 16\u201318, 2019; Philadelphia."},{"issue":"5","key":"1017_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamacardio.2023.0338","volume":"8","author":"AJ Kirtane","year":"2023","unstructured":"Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, et al. Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol. 2023;8(5):464\u201373.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1017_CR37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/HYPERTENSIONAHA.115.06260","volume":"66","author":"K Kario","year":"2015","unstructured":"Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights rrom SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015;66(6):1130\u20137.","journal-title":"Hypertension"},{"issue":"15","key":"1017_CR38","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1161\/CIRCULATIONAHA.118.035588","volume":"138","author":"K Kario","year":"2018","unstructured":"Kario K, Bohm M, Mahfoud F, Townsend RR, Weber MA, Patel M, et al. Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED trial. Circulation. 2018;138(15):1602\u20134.","journal-title":"Circulation"},{"issue":"2","key":"1017_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1161\/HYPERTENSIONAHA.119.13081","volume":"74","author":"K Kario","year":"2019","unstructured":"Kario K, Weber MA, Mahfoud F, Kandzari DE, Schmieder RE, Kirtane AJ, et al. Changes in 24-hour patterns of blood pressure in hypertension following renal denervation therapy. Hypertension. 2019;74(2):244\u20139.","journal-title":"Hypertension"},{"issue":"10333","key":"1017_CR40","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","volume":"399","author":"F Mahfoud","year":"2022","unstructured":"Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333):1401\u201310.","journal-title":"Lancet"},{"issue":"1","key":"1017_CR41","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41440-022-01042-8","volume":"46","author":"K Kario","year":"2023","unstructured":"Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023;46(1):280\u20138.","journal-title":"Hypertens Res"},{"issue":"4","key":"1017_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.120.16378","volume":"77","author":"K Kario","year":"2021","unstructured":"Kario K, Hettrick DA, Prejbisz A, Januszewicz A. Obstructive sleep apnea-induced neurogenic nocturnal hypertension: a potential role of renal denervation? Hypertension. 2021;77(4):1047\u201360.","journal-title":"Hypertension"},{"issue":"6","key":"1017_CR43","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1253\/circj.CJ-16-0035","volume":"80","author":"K Kario","year":"2016","unstructured":"Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, et al. Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension - insights from the SYMPLICITY HTN-3 trial. Circ J. 2016;80(6):1404\u201312.","journal-title":"Circ J"},{"issue":"11","key":"1017_CR44","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.hrthm.2022.06.031","volume":"19","author":"M Heradien","year":"2022","unstructured":"Heradien M, Mahfoud F, Greyling C, Lauder L, van der Bijl P, Hettrick DA, et al. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: randomized, sham-controlled trial. Heart Rhythm. 2022;19(11):1765\u201373.","journal-title":"Heart Rhythm"},{"issue":"3","key":"1017_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jama.2019.21187","volume":"323","author":"JS Steinberg","year":"2020","unstructured":"Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E, et al. Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial. JAMA. 2020;323(3):248\u201355.","journal-title":"JAMA"},{"issue":"5","key":"1017_CR46","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/jce.15004","volume":"32","author":"GM Prado","year":"2021","unstructured":"Prado GM, Mahfoud F, Lopes RD, Moreira DAR, Staico R, Damiani LP, et al. Renal denervation for the treatment of ventricular arrhythmias: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2021;32(5):1430\u20139.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"10","key":"1017_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010543","volume":"16","author":"KP Rommel","year":"2023","unstructured":"Rommel KP, Pagoulatou S, Kresoja KP, Rosch S, Schober AR, von Roeder M, et al. Modulation of pulsatile left ventricular afterload by renal denervation in heart failure with preserved ejection fraction. Circ Heart Fail. 2023;16(10): e010543.","journal-title":"Circ Heart Fail"},{"issue":"9","key":"1017_CR48","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/jch.14339","volume":"23","author":"H Kagitani","year":"2021","unstructured":"Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kobayashi D, Hiki S, et al. A Japan nationwide web-based survey of estimation on patients for renal denervation based on blood pressure level and the number of antihypertensives (J-NEEDs survey). J Clin Hypertens (Greenwich). 2021;23(9):1684\u201394.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"8","key":"1017_CR49","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41440-023-01333-8","volume":"46","author":"K Kario","year":"2023","unstructured":"Kario K, Kai H, Nanto S, Yokoi H. Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation. Hypertens Res. 2023;46(8):2044\u20137.","journal-title":"Hypertens Res"},{"key":"1017_CR50","doi-asserted-by":"crossref","unstructured":"Townsend RF, Kandzari K, Kario D, Mahfoud K, Weber F,Schmieder MA, Pocock R, Tsioufis S, David  K, Steigerwalt S, Walton S, Hopper T, Bertolet I, Calhoun B, Sharif W, Lurz F, Fengler P, Patel K, Fahy K, Hettrick M, Brar D, B\u00f6hm SM. Impact of antihypertensive medication changes on blood pressure after renal denervation among different patient groups in the SPYRAL HTN-ON MED trial. Hypertension 2024;in press.","DOI":"10.1161\/HYPERTENSIONAHA.123.22251"},{"issue":"2","key":"1017_CR51","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/HYPERTENSIONAHA.121.18534","volume":"79","author":"K Narita","year":"2022","unstructured":"Narita K, Hoshide S, Kario K. Nighttime home blood pressure is associated with the cardiovascular disease events risk in treatment-resistant hypertension. Hypertension. 2022;79(2):e18\u201320.","journal-title":"Hypertension"},{"issue":"19","key":"1017_CR52","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIRCULATIONAHA.120.049730","volume":"142","author":"K Kario","year":"2020","unstructured":"Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study. Circulation. 2020;142(19):1810\u201320.","journal-title":"Circulation"},{"issue":"3","key":"1017_CR53","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/HYPERTENSIONAHA.121.17440","volume":"78","author":"K Kario","year":"2021","unstructured":"Kario K, Williams B. Nocturnal hypertension and heart failure: mechanisms, evidence, and new treatments. Hypertension. 2021;78(3):564\u201377.","journal-title":"Hypertension"},{"issue":"10393","key":"1017_CR54","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(23)00733-X","volume":"401","author":"N Staplin","year":"2023","unstructured":"Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet. 2023;401(10393):2041\u201350.","journal-title":"Lancet"},{"issue":"9594","key":"1017_CR55","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(07)61538-4","volume":"370","author":"J Boggia","year":"2007","unstructured":"Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bj\u00f6rklund-Bodeg\u00e5rd K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219\u201329.","journal-title":"Lancet"},{"issue":"14","key":"1017_CR56","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1161\/01.CIR.0000160923.04524.5B","volume":"111","author":"R Sega","year":"2005","unstructured":"Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111(14):1777\u201383.","journal-title":"Circulation"},{"issue":"2","key":"1017_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41440-021-00761-8","volume":"45","author":"Y Ogoyama","year":"2022","unstructured":"Ogoyama Y, Tada K, Abe M, Nanto S, Shibata H, Mukoyama M, et al. Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res. 2022;45(2):210\u201320.","journal-title":"Hypertens Res"},{"issue":"6","key":"1017_CR58","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/HYPERTENSIONAHA.121.18198","volume":"78","author":"K Kario","year":"2021","unstructured":"Kario K, Hoshide S, Narita K, Okawara Y, Kanegae H. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: the JAMP study. Hypertension. 2021;78(6):1781\u201390.","journal-title":"Hypertension"},{"issue":"13","key":"1017_CR59","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jacc.2016.01.037","volume":"67","author":"K Kario","year":"2016","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, et al. Morning home blood pressure Is a strong predictor of coronary artery disease: the HONEST study. J Am Coll Cardiol. 2016;67(13):1519\u201327.","journal-title":"J Am Coll Cardiol"},{"issue":"10361","key":"1017_CR60","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(22)01787-1","volume":"400","author":"DL Bhatt","year":"2022","unstructured":"Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400(10361):1405\u201316.","journal-title":"Lancet"},{"issue":"1","key":"1017_CR61","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/HYPERTENSIONAHA.116.07201","volume":"68","author":"S Hoshide","year":"2016","unstructured":"Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Morning and evening home blood pressure and risks of incident stroke and coronary artery disease in the Japanese general practice population: the Japan morning surge-home blood pressure study. Hypertension. 2016;68(1):54\u201361.","journal-title":"Hypertension"},{"issue":"20","key":"1017_CR62","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.jacc.2022.08.802","volume":"80","author":"F Mahfoud","year":"2022","unstructured":"Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol. 2022;80(20):1871\u201380.","journal-title":"J Am Coll Cardiol"},{"key":"1017_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-00023-02325-x","author":"F Mahfoud","year":"2023","unstructured":"Mahfoud F, Azizi M, Daemen J, Sharp ASP, Patak A, Iglesias JF, et al. Real-world experience with ultrasound renal denervation utilizing home blood pressure monitoring: the Global Paradise System registry study design. Clin Res Cardiol. 2023. https:\/\/doi.org\/10.1007\/s00392-00023-02325-x.","journal-title":"Clin Res Cardiol"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-024-01017-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-024-01017-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-024-01017-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T05:09:48Z","timestamp":1727413788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-024-01017-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1007\/s12928-024-01017-1","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kario K receives grants from A&D, Omron Healthcare, Fukuda Denshi, CureApp, Sanwa Kagaku Kenkyusho; Honoraria from Daichi Sankyo, Viatris, Novartis, Otsuka Pharmaceuticals, Medtronic, Otsuka Medical device, Omron Healthcare. Kai H receives honoraria from Daiichi Sankyo, Novartis and Otsuka Medical Device. Rakugi H receives honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Otsuka Pharmaceutical Co., Ltd.; research funding from Novartis Pharma K.K.; scholarship from Daiichi Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd. Takeda Pharmaceutical Company Ltd., and Sumitomo Pharma, Co., Ltd. Hoshide S receives honoraria from Novartis. Node K receives research grants from Otsuka Medical Devices, Medtronic, Astellas, Bayer Yakuhin, Boehringer Ingelheim Japan, Fujiyakuhin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Novartis Pharma; Scholarship from Abbott, Boehringer Ingelheim Japan, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Teijin Pharma; Honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Otsuka, Tsumura & Co. Maekawa Y receives Scholarship funds or Donations Scholarship funds from Abbott Medical Japan LLC, and BIOTRONIK JAPAN. Tsutsui H receives consultancy from Boehringer Ingelheim Co., Ltd., Bayer Yakuhin, Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Astra Zeneca Co., Ltd.; Remuneration from MSD K.K., Astellas Pharma Inc., Pfizer Japan Inc., Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Company Limited, Bayer Yakuhin, Ltd., Novartis Pharma K.K., Kowa Pharmaceutical Co. Ltd., Teijin Pharma Ltd.; Manuscript fees from Medical View, Nippon Rinsho; Research funding from Actelion Pharmaceuticals Japan Ltd., Japan Tobacco Inc., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., IQVIA Services Japan, Omron Healthcare; Scholarship funds from Astellas Pharma Inc., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Ltd., MSD K.K. Sakata Y receives grants from Abbott Medical Japan, Otsuka Pharmaceutical, Nippon Boehringer Ingelheim, Boston Scientific Japan, BIOTRONIK JAPAN; Honoraria from AstraZeneca, Otsuka Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma and Bayer Yakuhin. Aoki J receives Honoraria from Medtronic, Otsuka Medical Device, Otsuka Pharmaceutical, and Daiichi Sankyo. Nanto S receives Honoraria from Medtronic, Otsuka Medical device. Yokoi H receives Honoraria from Daiichi Sankyo, Medtronic, Otsuka Medical device. Role of clinical trials: Kario K\u00a0is an executive committee principal investigator for the Spyral OFF MED, the Spyral ON MED, the DUO and the REQUIRE; a coordinating investigator for the TCD-16164 study; a site principal investigator for the HTN-J, the Spyral OFF MED, the Spyral ON MED, the DUO, the REQUIRE and the TCD-16164 study. Kai H\u00a0is a site sub-investigator for the HTN-J; a medical expert for the DUO and the REQUIRE. Rakugi H\u00a0is a site sub-investigator for the HTN-J, the DUO and the REQUIRE. Hoshide S\u00a0is a site sub-investigator for the HTN-J, the Spyral OFF MED, the Spyral ON MED, the DUO, the REQUIRE and the TCD-16164 study.; a medical expert for the REQUIRE. Node K\u00a0is a site sub investigator for the REQUIRE. Maekawa Y\u00a0is a site principal investigator for the DUO. Sakata Y is a principal investigator for the DUO and the REQUIRE; a site sub-investigator for the HTN-J. Aoki J is a site sub investigator for the HTN-J; a site principal investigator for the Spyral OFF MED, the Spyral ON MED studies, the DUO and the REQUIRE. Nanto S\u00a0is an executive committee principal investigator for the DUO and the REQUIRE; a member of the advisory team for ablation site for the REQUIRE; a site principal investigator for the REQUIRE. Yokoi H\u00a0is a site principal investigator for the DUO, the REQUIRE and the TCD-16164 study;. an advisor on renal artery access for the REQUIRE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}